Viking Therapeutics Inc (VKTX)

Weight Loss · registered primary completion 2027-07-01 · NCT07104500

Published 2026-09-02Market cap $3,752M7 sourced statements

VK2735 for Weight Management Phase 3 · PHASE3 · n=4500 · active not recruiting

Market

fact

4 approved products already carry Weight Loss on label, including AZSTARYS, Ursodiol, Megestrol Acetate, Omega-3-acid ethyl esters. Approval would enter an occupied market.

Source: FDA label index

Trial registry

fact

Registered design for NCT07104500: randomized, triple-masked, 4500 participants (estimated). Primary outcome: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $502M against operating outflow of $117M per quarter gives roughly 4.3 quarters of runway, clearing the registered primary completion 3.4 quarters out by 0.9 quarters.

Source: 10-Q filed 2026-07-29

Share count and dilution

fact

116,652,937 shares outstanding against 124,486,664 if every outstanding option, warrant and convertible were exercised. In that case 6.3% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-07-29

Regulatory

fact

Designations disclosed: Orphan Drug. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-07-29

Pipeline

fact

1 distinct molecule in 2 active company-sponsored trials; VK2735 accounts for 2 of them at Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 5.3%.

Source: DEF 14A filed 2026-04-01

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.